选择性氧酶增殖器激活的受体α调节器改善了慢性病患者的高三糖血症和肌肉质量:一项回顾性观察性研究
Yukari Mae1, Tomoaki Takata1, Sosuke Taniguchi1
1Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Clinical nutrition ESPEN
|November 27, 2024
概括
选择性氧酶增殖器激活受体α调节剂 (SPPARMα) 在慢性病 (CKD) 患者中有效降低甘油三. 与传统治疗不同,SPPARMα还改善了肌肉质量,这表明了CKD管理的新治疗途径.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 慢性病 (CKD) 与肉症和子宫外脂肪积累有关,影响肌肉质量和身体功能.
- 过高甘油三和脂质失调是CKD的关键代谢异常,有助于宫外脂肪沉积.
- 选择性氧酶增殖器激活受体α调节剂 (SPPARMα) 是新兴的高甘油三血症治疗方法,但它们对CKD患者的肌肉质量的影响尚不清楚.
研究的目的:
- 评估SPPARMα在治疗慢性病患者的高甘油三血症中的疗效.
- 评估SPPARMα对肌肉质量的影响,通过相角测量,在这个患者群体中.
- 为了比较SPPARMα与传统的降脂疗法对脂质配置,功能和肌肉质量的影响.
主要方法:
- 一项回顾性观察性研究包括患有失脂症的CKD患者,他们开始服用高甘油三血症药物.
- 患者被分为两组:接受SPPARMα的患者和接受常规治疗的患者 (他类药物,ezetimibe,eicosapentaenoic acid,纤维化物).
- 在6个月的时间里,脂质样本,功能 (eGFR,尿蛋白) 和肌肉质量 (相位角度) 进行了比较.
主要成果:
- SPPARMα显著降低了甘油三 (TG) 从296.8至153.0毫克/分升 (p < 0.001),没有对功能产生不良影响.
- 传统的治疗也改善了TG水平 (从261.6到173.6毫克/分升,p<0.001).
- 只有SPPARMα组表现出肌肉质量的显著改善,相角从5.41增加到5.55 (p < 0.05).
结论:
- 在CKD患者中,SPPARMα有效降低KD患者的TG,并保持功能.
- 在CKD患者中,SPPARMα治疗独特地改善了肌肉质量,这表明除了减少脂质之外的好处.
- 这些发现凸显了SPPARMα作为CKD患者的有前途的治疗选择,特别是那些同时患有肌肉质量低下和高甘油三血的人.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
536
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
536
Cholesterol: Significance and Regulation
510
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
510
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141


